Significance of quantitative assay of CD35、CD44s and CD58 expressed on erythrocytes in patients with lung cancer

Objective: To investigate the relationship between quantitative molecule expresssion of CD35,CD44s and CD58 on erythrocytes and types of pathology,stages and before and after chemical treatment in lung cancer.Methods: Glutaraldehyde-fixed red blood cells were analyzed in ‘V’ microtitre plates,mouse monoclonal antihuman CD35,CD44s and CD58 were added in order.After immunoenzymic reaction process in the plates,the red bloodcell supernatant was transferred to a clean microtitre plate and read at 405nm (A405).Results: Except poorly differentiated lung cancer,CD35,CD44s and CD58 expressed were significantly lower on erythrocytes in various pathologic types in lung cancer groups than in control group.The difference was significant(P<0.05 and P<0.01).The difference was not significant in CD35,CD44s and CD58 expressed(P<0.05) on erythrocytes in various pathologic types of lung cancer (P>0.05).It showed that quantitative molecule expression of CD35,CD44s and CD58 in the patients with lung cancer in Ⅲ and Ⅳ stages were significantly lower than that in Ⅰ and Ⅱ stages(P<0.05).Compared with the patients with lung cancer before chemical treatment,expression of CD35 was significantly lower in the patients with lung cancer after chemical treatment.There was no significant difference between CD44s and CD58 molecule expressions(P>0.05).Conclusions: Our data suggest that quantitative molecule expression of CD35,CD44s and CD58 on erythrocytes in the patients with lung cancer is lower than normal and the erythrocytes immuno function descends with the aggravation of the disease.Furthermore,this data displays that change of CD35,CD44s and CD58 quantities expression on erythrocytes is associated with metastasis and deterioration of the tumor in the patients with lung cancer,which may be of importantce to the development and prognosis of lung cancer.